GSK says Mo-rez could have blockbuster potential

GSK reported early data showing its experimental drug Mo-rez produced at least 30% tumor shrinkage in 62% of platinum-resistant ovarian cancer patients and 67% of endometrial cancer patients; the drug is in late-stage trials and the company plans further studies.

GSK reported early clinical results for its experimental targeted cancer drug Mo-rez, presenting data at a medical conference in Puerto Rico. Company officials described Mo-rez as a priority asset and said it could have blockbuster potential. The announcement follows a wider push in GSK’s oncology work under its new CEO. The drug was licensed from Hansoh Pharma in 2023 and is being advanced in multiple studies. Key details: - The trial measured meaningful tumor reduction as at least 30% shrinkage. - In platinum-resistant ovarian cancer, 62% of patients met that 30% reduction threshold. - In endometrial cancer, 67% of patients met the same threshold. - GSK is testing Mo-rez in two late-stage trials in ovarian and endometrial cancers and plans to start three additional studies in the coming months. - Mo-rez is an antibody-drug conjugate that targets the B7H4 protein, which the article reports is found on gynecological cancer cells and largely absent from healthy tissue. Summary: The reported results have given momentum to GSK's oncology business, reflecting comments from company leaders about accelerating drug development. The company is continuing late-stage testing of Mo-rez and plans additional studies; analysts have not yet projected future sales and further trial data will shape the clinical and commercial outlook.